KONEXBiotech & Pharma251280

AngioLab

₩2,100▲ 0.72%2026-11-18 close
Market Cap
₩7.7B
Turnover
₩44,100
Volume
21 shares
Shares out.
3.7M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Angiogenesis pipeline and a loss-making base

AngioLab shows revenue growth and a narrower operating loss, while the timing of pipeline monetization and future funding remain the key variables for this KONEX-listed biotech.

  1. 1

    Fiscal 2025 revenue reached KRW 2,265 million, up 10.8% from the prior year on an aggregated financial data basis.

  2. 2

    The operating loss narrowed to KRW 603 million from KRW 847 million in 2024, marking a second consecutive year of smaller losses.

  3. 3

    A large share of revenue comes from health functional food ingredients and finished products built on the Ob-X lemon balm extract blend.

  4. 4

    ALS-L1023, a candidate for wet age-related macular degeneration, received MFDS approval for its Phase 3 IND in September 2024, and its otitis media with effusion indication completed Phase 2a.

  5. 5

    At the March 2026 general meeting, the financial statement proposal passed, though the approval rate against total issued voting shares was recorded at 49.3%.

02

Business structure

AngioLab is a Daejeon-based biotech founded in 1999 that pursues drug development and health functional foods around its angiogenesis inhibition technology.

The company holds an in-house screening platform called ANGIOTOS, which measures and screens angiogenesis inhibition, and uses it to develop natural product drugs and antibody therapeutics. Revenue is concentrated in health functional foods.

According to business reports, sales of the Ob-X lemon balm extract blend as an ingredient ranged from the high 50s to the high 70s percent of total sales in different years, with finished products accounting for the rest. The lead pipeline asset is ALS-L1023 for wet age-related macular degeneration.

The same compound completed a Phase 2a trial in adults with otitis media with effusion, and related composition patents were granted in the United States and Japan.

In antibodies, the company is developing a photoimmunotherapy anticancer platform that pairs a photosensitizer with an antibody, and it has reportedly secured in vitro proof of concept and is preparing in vivo efficacy studies.

At the end of 2025, the company filed a domestic patent for a new cell-penetrating peptide technology and proposed applications in skin, eye, and hair loss. On the cosmetic side, its SPACE peptide skin-penetration platform obtained an International Nomenclature of Cosmetic Ingredients name.

Compared with large pharmaceutical and biotech peers, its capital and headcount base is small, with roughly 16 to 17 employees reported. The business therefore remains weighted toward health functional food sales rather than clinical-stage pipeline revenue.

03

Recent trends

According to the separate financial statements for fiscal 2025 (the 27th term), filed on March 26, 2026, revenue was KRW 2,265 million. The operating loss was KRW 603 million and the net loss was KRW 554 million.

Total assets stood at KRW 2,699 million, total liabilities at KRW 1,058 million, and total equity at KRW 1,641 million. The independent auditor issued an unqualified opinion on the separate statements.

According to an aggregated financial data provider, 2024 revenue was KRW 2,045 million and the operating loss was KRW 848 million. On that basis, 2025 revenue rose 10.8% year on year and the operating loss shrank by more than KRW 200 million.

The same data show a 2023 operating loss of KRW 2,434 million, so losses narrowed in both 2024 and 2025. At the March 2026 general meeting, the financial statement proposal passed, with the approval rate against total issued voting shares recorded at 49.3%.

On the capital side, a disclosure on a rights offering decision was filed in February 2025, and disclosures on conversion of convertible preferred shares into common shares followed in April and July 2025.

In September 2026, a disclosure on the exercise of conversion rights for convertible shares was filed, along with executive and major shareholder holding reports. According to Morningstar, the share price was KRW 1,900 on August 7, 2026, within a 52-week range of KRW 1,523 to KRW 4,635. The share price used in this report is KRW 2,155, with zero trading value.

04

Outlook

The outlook will depend on clinical progress and whether the company secures funding. ALS-L1023 has approval for its Phase 3 IND, so the start of Phase 3 and its results are the next major milestones.

For the otitis media with effusion indication, the entry into a later stage after the completed Phase 2a trial is the item to watch.

On patents, the lemon balm fraction patent has been granted in the United States and Japan, while the new cell-penetrating peptide technology remains at the domestic filing stage, leaving registration and overseas filings ahead.

For the photoimmunotherapy anticancer platform, the transition from in vitro proof of concept to in vivo efficacy studies is an important turning point.

Health functional food sales showed growth in 2025, but whether ingredient and finished product sales are sustained depends on expansion of sales channels and customers.

In cosmetics, the International Nomenclature of Cosmetic Ingredients name has been obtained, so whether co-development with beauty brands translates into actual revenue is the point to track.

On capital, with total equity at KRW 1,641 million and an annual operating loss around KRW 600 million, repeated fundraising to cover clinical costs is possible. This could lead to dilution and changes in share count, so rights offering and convertible share disclosures should be read together.

05

Bull factors

Revenue growth and narrowing losses

Revenue rose 10.8% in 2025 on an aggregated basis, and the operating loss narrowed from KRW 847 million in 2024 to KRW 603 million. Two consecutive years of narrower losses are cited as evidence that the cost structure is becoming somewhat more stable.

Because sales come from health functional foods, the company's cash burn is discussed as being managed at a certain pace even while clinical spending continues.

Clinical-stage pipeline and patent protection

ALS-L1023 received MFDS approval for its Phase 3 IND in September 2024 and completed a Phase 2a trial in adults with otitis media with effusion. The related composition patents were granted in the United States and Japan, so protection extends beyond Korea.

Advancing candidates into clinical stages is viewed by supporters as meaningful progress for a company of this size.

Platform expansion and diversified applications

At the end of 2025, the company filed a domestic patent application for a new cell-penetrating peptide technology and presented potential delivery in skin, eye, and hair applications. The photoimmunotherapy anticancer platform is reported to have secured in vitro proof of concept.

The SPACE peptide cosmetic ingredient obtaining an INCI name is cited as an example of the platform being applied beyond medicines. Supporters argue that diversified applications could soften the impact of any single pipeline setback.

06

Bear factors

Small revenue base and continuing losses

Revenue was KRW 2,265 million in 2025, a small base, while the operating loss of KRW 603 million and net loss of KRW 554 million continued. Total liabilities of KRW 1,058 million against total assets of KRW 2,699 million limit the room for financial flexibility.

Because most revenue comes from health functional foods, the pipeline is still a long way from contributing to earnings.

Frequent capital raising and share structure changes

A third-party rights offering was disclosed in 2021, and a rights offering decision was disclosed in February 2025. Disclosures on conversion of convertible preferred shares into common shares occurred twice in 2025. In September 2026, a disclosure on the exercise of conversion rights for convertible shares was filed. These changes affect the share count and float, and continued funding needs could lead to further raises.

Small float and general meeting approval rate

Market capitalization is about KRW 7.9 billion, and according to Morningstar, the 52-week price range was wide, from KRW 1,523 to KRW 4,635. The current price of KRW 2,155 is set against zero trading value. The approval share relative to total issued voting shares at the next general meeting is the point to check. Thinly traded small KONEX stocks are seen as more exposed to price volatility and gaps in quotes.

07

Risk factors

Macro

Funding for biotech companies is sensitive to interest rate levels and investor appetite for risk assets. If capital market conditions weaken, rights offering terms can become less favorable, raising dilution concerns.

Small KONEX names tend to feel the effects of liquidity contraction more sharply when overall market sentiment shifts.

Clinical and regulatory

ALS-L1023 has approval for its Phase 3 IND, but Phase 3 results and any marketing approval remain undetermined. The otitis media with effusion indication will also depend on outcomes of later development stages after the Phase 2a trial.

The antibody and peptide platforms still require in vivo efficacy and safety validation, so timelines could slip.

Liquidity and capital structure

With total equity of KRW 1,641 million against an annual operating loss near KRW 600 million, funding clinical spending from internal cash is difficult. Repeated convertible share conversions and rights offerings could bring per-share dilution and supply pressure.

As a small cap with market capitalization of about KRW 7.9 billion, the stock also carries structural risk of large price moves on sizable trades.

08

Overall view

AngioLab is a KONEX-listed biotech pursuing natural product drugs, antibodies, and peptide platforms built on angiogenesis inhibition technology. For fiscal 2025, revenue was KRW 2,265 million, up 10.8% year on year, and the operating loss of KRW 603 million was smaller than in 2024.

In clinical development, the Phase 3 IND approval for ALS-L1023 and the completion of a Phase 2a trial in otitis media with effusion are the main recorded milestones. Bullish factors cited include revenue growth, narrower losses, patent grants, and platform expansion.

Bearish factors cited include a small revenue base with continuing losses, repeated capital raising and convertible share conversions, and thin liquidity with a 49.3% approval rate at the general meeting.

Given a market capitalization of about KRW 7.9 billion and a wide 52-week price range, price volatility is typical of a small cap. Whether clinical trials progress and how additional funding is raised will be revealed through future disclosures, and the weight of the business assessment will shift accordingly. This verdict is a qualitative summary based on disclosures and press reports, provided for information only.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 10 more articles and sources
  1. m.news.nate.com
  2. saramin.co.kr
  3. m.irgo.co.kr
  4. pharmnews.com
  5. newspim.com
  6. kind.krx.co.kr
  7. kind.krx.co.kr
  8. medipharmhealth.co.kr
  9. morningstar.com
  10. marketbz.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis